Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1109717

	registered interest
	date	04/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bipolar Disorder: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent discussions he has had with representatives of the NHS on the availability of drugs to treat bi-polar disorders in the event that the UK leaves the EU without a deal.
	tabling member constituency	Hornsey and Wood Green
	tabling member printed	Catherine West
	uin	241072
	answer	answer is ministerial correction date of answer 09/04/2019 answer text <p>Leaving the European Union with a ‘deal’ remains the Government’s top priority and would give businesses stability and certainty to prepare for our new relationship with the EU after EU exit. The Department has published guidance to industry and the health and care system to allow them to make informed plans and preparations. This is available on GOV.UK.</p><p> </p><p>On 26 March, we wrote to all other organisations in the health and care system to ask them to continue to prepare for leaving the EU without a ‘deal’.</p><p> </p><p>My Rt. hon. Friend the Secretary of State for Health and Social Care discusses ‘no deal’ contingency plans, including those for the availability of medicines, with a number of stakeholders, including the National Health Service and other Government Departments.</p><p> </p><p>The Department has been working closely with trade bodies, product suppliers, the NHS in England, and the devolved administrations and the Crown Dependencies, to ensure the continuation of the supply of medicines to the whole of the United Kingdom in the event of a ‘no deal’ EU exit. This includes the NHS, social care and the independent sector, and covers licensed medicines (prescription only, pharmacy and general sales list medicines) and unlicensed medicines (specials, investigational medicinal products and UK imports).</p><p> </p><p>We understand that medicines to treat conditions such as epilepsy, bi-polar disorder and neuropathic pain are vitally important to many people in this country. Our contingency plans include sensible mitigations for medicines that come to the UK from or via the EU/European Economic Area, such as precautionary stockpiling by suppliers, to ensure that the supply of essential medicines to patients is not disrupted.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 241073 241074 241075 question first answered 09/04/2019 16:00:30 answering member 1585 label Biography information for Stephen Hammond
	tabling member	4523 label Biography information for Catherine West

1109718

	registered interest
	date	04/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Epilepsy: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent discussions he has had with representatives of the NHS on the availability of drugs to treat epilepsy in the event of that the UK leaves the EU without a deal.
	tabling member constituency	Hornsey and Wood Green
	tabling member printed	Catherine West
	uin	241073
	answer	answer is ministerial correction date of answer 09/04/2019 answer text <p>Leaving the European Union with a ‘deal’ remains the Government’s top priority and would give businesses stability and certainty to prepare for our new relationship with the EU after EU exit. The Department has published guidance to industry and the health and care system to allow them to make informed plans and preparations. This is available on GOV.UK.</p><p> </p><p>On 26 March, we wrote to all other organisations in the health and care system to ask them to continue to prepare for leaving the EU without a ‘deal’.</p><p> </p><p>My Rt. hon. Friend the Secretary of State for Health and Social Care discusses ‘no deal’ contingency plans, including those for the availability of medicines, with a number of stakeholders, including the National Health Service and other Government Departments.</p><p> </p><p>The Department has been working closely with trade bodies, product suppliers, the NHS in England, and the devolved administrations and the Crown Dependencies, to ensure the continuation of the supply of medicines to the whole of the United Kingdom in the event of a ‘no deal’ EU exit. This includes the NHS, social care and the independent sector, and covers licensed medicines (prescription only, pharmacy and general sales list medicines) and unlicensed medicines (specials, investigational medicinal products and UK imports).</p><p> </p><p>We understand that medicines to treat conditions such as epilepsy, bi-polar disorder and neuropathic pain are vitally important to many people in this country. Our contingency plans include sensible mitigations for medicines that come to the UK from or via the EU/European Economic Area, such as precautionary stockpiling by suppliers, to ensure that the supply of essential medicines to patients is not disrupted.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 241072 241074 241075 question first answered 09/04/2019 16:00:30 answering member 1585 label Biography information for Stephen Hammond
	tabling member	4523 label Biography information for Catherine West

1109719

	registered interest
	date	04/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Nervous System: Pain
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent discussions he has had with representatives of the NHS on the availability of drugs to treat neuropathic pain in the event that the UK leaves the EU without a deal.
	tabling member constituency	Hornsey and Wood Green
	tabling member printed	Catherine West
	uin	241074
	answer	answer is ministerial correction date of answer 09/04/2019 answer text <p>Leaving the European Union with a ‘deal’ remains the Government’s top priority and would give businesses stability and certainty to prepare for our new relationship with the EU after EU exit. The Department has published guidance to industry and the health and care system to allow them to make informed plans and preparations. This is available on GOV.UK.</p><p> </p><p>On 26 March, we wrote to all other organisations in the health and care system to ask them to continue to prepare for leaving the EU without a ‘deal’.</p><p> </p><p>My Rt. hon. Friend the Secretary of State for Health and Social Care discusses ‘no deal’ contingency plans, including those for the availability of medicines, with a number of stakeholders, including the National Health Service and other Government Departments.</p><p> </p><p>The Department has been working closely with trade bodies, product suppliers, the NHS in England, and the devolved administrations and the Crown Dependencies, to ensure the continuation of the supply of medicines to the whole of the United Kingdom in the event of a ‘no deal’ EU exit. This includes the NHS, social care and the independent sector, and covers licensed medicines (prescription only, pharmacy and general sales list medicines) and unlicensed medicines (specials, investigational medicinal products and UK imports).</p><p> </p><p>We understand that medicines to treat conditions such as epilepsy, bi-polar disorder and neuropathic pain are vitally important to many people in this country. Our contingency plans include sensible mitigations for medicines that come to the UK from or via the EU/European Economic Area, such as precautionary stockpiling by suppliers, to ensure that the supply of essential medicines to patients is not disrupted.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 241072 241073 241075 question first answered 09/04/2019 16:00:30 answering member 1585 label Biography information for Stephen Hammond
	tabling member	4523 label Biography information for Catherine West

1109720

	registered interest
	date	04/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, which drugs has his Department identified as at risk of shortage in the event that the UK leaves the EU without a deal.
	tabling member constituency	Hornsey and Wood Green
	tabling member printed	Catherine West
	uin	241075
	answer	answer is ministerial correction date of answer 09/04/2019 answer text <p>Leaving the European Union with a ‘deal’ remains the Government’s top priority and would give businesses stability and certainty to prepare for our new relationship with the EU after EU exit. The Department has published guidance to industry and the health and care system to allow them to make informed plans and preparations. This is available on GOV.UK.</p><p> </p><p>On 26 March, we wrote to all other organisations in the health and care system to ask them to continue to prepare for leaving the EU without a ‘deal’.</p><p> </p><p>My Rt. hon. Friend the Secretary of State for Health and Social Care discusses ‘no deal’ contingency plans, including those for the availability of medicines, with a number of stakeholders, including the National Health Service and other Government Departments.</p><p> </p><p>The Department has been working closely with trade bodies, product suppliers, the NHS in England, and the devolved administrations and the Crown Dependencies, to ensure the continuation of the supply of medicines to the whole of the United Kingdom in the event of a ‘no deal’ EU exit. This includes the NHS, social care and the independent sector, and covers licensed medicines (prescription only, pharmacy and general sales list medicines) and unlicensed medicines (specials, investigational medicinal products and UK imports).</p><p> </p><p>We understand that medicines to treat conditions such as epilepsy, bi-polar disorder and neuropathic pain are vitally important to many people in this country. Our contingency plans include sensible mitigations for medicines that come to the UK from or via the EU/European Economic Area, such as precautionary stockpiling by suppliers, to ensure that the supply of essential medicines to patients is not disrupted.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 241072 241073 241074 question first answered 09/04/2019 16:00:30 answering member 1585 label Biography information for Stephen Hammond
	tabling member	4523 label Biography information for Catherine West

1109795

	registered interest
	date	04/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what contingency plans his Department has to mitigate (a) staff and (b) pharmaceutical shortages in the event of the UK leaving the EU without a deal.
	tabling member constituency	Dulwich and West Norwood
	tabling member printed	Helen Hayes
	uin	241063
	answer	answer is ministerial correction date of answer 09/04/2019 answer text <p>The Department continues to monitor and analyse overall staffing levels in the health and social care sectors and we have been monitoring leaver and joiner rates of European Union staff on a regular basis since the 2016 referendum. While we do not expect our exit from the EU to lead to a significant number of health staff leaving on or around exit day, we are not complacent and are continually monitoring staffing levels and working with other Government Departments and local areas to put in place mechanisms to respond to any shortages.</p><p> </p><p>We hugely value the contribution of EU staff working in health and social care and the Government has made it clear that we want them to stay. That is why EU staff in health and social care have had early access to the EU Settlement Scheme since December 2018, allowing them to secure their rights to live and work in the United Kingdom. In March 2019, we put in place legislation that ensures the continued recognition of qualifications from EU countries by all professional regulators covering the health and social care sectors. This means EU staff who are currently practising in the UK can continue to do so, and that professionals qualified in the European Economic Area and Switzerland can continue to apply for registration after ‘exit day’, even if we leave without a ‘deal’.</p><p> </p><p>Furthermore, the NHS Long Term Plan sets out a vital strategic framework to ensure that over the next 10 years the National Health Service will have the staff it needs, so that nurses and doctors can administer the expert compassionate care they are committed to providing. Baroness Dido Harding, Chair of NHS Improvement, working closely with Sir David Behan, Chair of Health Education England, will lead a number of programmes to develop a detailed workforce implementation plan. Baroness Harding and Sir David will present these initial recommendations to the Department this spring.</p><p> </p><p>On medicines, the Department has been working closely with trade bodies, product suppliers, the NHS in England, and the devolved administrations and Crown Dependencies, to ensure the continuation of the supply of medicines to the whole of the UK in the event of a ‘no deal’ EU exit. This includes the NHS, social care and the independent sector and covers licensed medicines (prescription only, pharmacy and general sales list medicines) and unlicensed medicines (specials, investigational medicinal products and UK imports).</p><p> </p><p>The Department, together with industry and the NHS, has analysed the supply chains of 12,300 medicines and we are grateful for excellent engagement from all parties, which means our plans are well advanced. As a result of this analysis, the Department has put in place a multi-layered approach to minimise any supply disruption.</p><p> </p><p>We are confident that, if everyone does what they need to do, the supply of medicines and medical products will be uninterrupted in the event of exiting the EU without a deal.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 09/04/2019 16:01:41 answering member 1585 label Biography information for Stephen Hammond
	tabling member	4510 label Biography information for Helen Hayes